{
"id":"mk19_b_pm_t18",
"number":18,
"bookId":"pm",
"title":{
"__html":"Selected Drug-Induced Parenchymal Lung Diseases"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"29b025",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 18. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_pm_t18"
}
]
},
"Selected Drug-Induced Parenchymal Lung Diseases"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43e754",
"class":"col hd l",
"children":[
"Clinical Points"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea67d7",
"class":"col hd l",
"children":[
"Radiographic Findings and Treatment"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fccce3",
"class":"cell txt l",
"children":[
"Amiodarone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e344a7",
"class":"cell txt l",
"children":[
"More common in:"
]
},
" ",
{
"type":"p",
"hlId":"dd2ff2",
"class":"cell txt li",
"children":[
"Older patients"
]
},
" ",
{
"type":"p",
"hlId":"55ca45",
"class":"cell txt li",
"children":[
"Increased dosage and higher cumulative dose"
]
},
" ",
{
"type":"p",
"hlId":"769290",
"class":"cell txt li",
"children":[
"First year of therapy (but can occur late)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c56efc",
"class":"cell txt l",
"children":[
"Multiple radiographic presentations possible, including ground-glass opacities, subpleural nodules, and reticular abnormalities"
]
},
" ",
{
"type":"p",
"hlId":"0e1c56",
"class":"cell txt l",
"children":[
"Very long half-life prevents clearance from the pulmonary parenchyma:"
]
},
" ",
{
"type":"p",
"hlId":"a6215c",
"class":"cell txt li",
"children":[
"Rare improvement with discontinuation of the drug alone"
]
},
" ",
{
"type":"p",
"hlId":"04f86b",
"class":"cell txt li",
"children":[
"High risk for recurrence with tapering of glucocorticoids"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98cff",
"class":"cell txt l",
"children":[
"Methotrexate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"418d6b",
"class":"cell txt l",
"children":[
"Occurs in less than 5% of treated patients"
]
},
" ",
{
"type":"p",
"hlId":"49ec29",
"class":"cell txt l",
"children":[
"Unpredictable time to presentation"
]
},
" ",
{
"type":"p",
"hlId":"b4fc64",
"class":"cell txt l",
"children":[
"No clear correlation between dose and disease severity"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6a4f4",
"class":"cell txt l",
"children":[
"Diffuse reticular and ground-glass attenuation"
]
},
" ",
{
"type":"p",
"hlId":"ac3f0e",
"class":"cell txt l",
"children":[
"Patients generally do well after stopping medication"
]
},
" ",
{
"type":"p",
"hlId":"f0010c",
"class":"cell txt l",
"children":[
"Glucocorticoids are often given; duration is based on response"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc99ce",
"class":"cell txt l",
"children":[
"Nitrofurantoin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37c935",
"class":"cell txt l",
"children":[
"Acute (more common):"
]
},
" ",
{
"type":"p",
"hlId":"327f96",
"class":"cell txt li",
"children":[
"Fevers, chills, cough, shortness of breath, chest pain; rash can occur in 10%-20% of patients"
]
},
" ",
{
"type":"p",
"hlId":"c744cb",
"class":"cell txt li",
"children":[
"Peripheral eosinophilia common"
]
},
" ",
{
"type":"p",
"hlId":"5e0187",
"class":"cell txt l",
"children":[
"Chronic:"
]
},
" ",
{
"type":"p",
"hlId":"8d454a",
"class":"cell txt li",
"children":[
"Distinct from the acute form"
]
},
" ",
{
"type":"p",
"hlId":"3dcf62",
"class":"cell txt li",
"children":[
"Onset months to years after prolonged exposure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5a66b",
"class":"cell txt l",
"children":[
"Acute: Faint bilateral lower lobe septal lines; moderate pleural effusions may be present; often resolves with discontinuation but will recur with repeat exposure"
]
},
" ",
{
"type":"p",
"hlId":"00a277",
"class":"cell txt l",
"children":[
"Chronic: Reticular opacities with subpleural lines and thickened peri-bronchovascular areas; possible benefit of glucocorticoids from anecdotal reports"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6036f5",
"class":"cell txt l",
"children":[
"Busulfan"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c8a21",
"class":"cell txt l",
"children":[
"Occurs in less than 8% of treated patients"
]
},
" ",
{
"type":"p",
"hlId":"da001c",
"class":"cell txt l",
"children":[
"Currently used solely as a preparative regimen for HSCT; often combined with other agents associated with pulmonary toxicity"
]
},
" ",
{
"type":"p",
"hlId":"d58248",
"class":"cell txt l",
"children":[
"Injury typically occurs 30 days to 1 year after exposure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34b5f9",
"class":"cell txt l",
"children":[
"Multiple patterns, including ground-glass opacities, reticulation, bibasilar septal lines, asymmetric peripheral and peribronchial consolidation, centrilobular nodules, and dependent consolidation"
]
},
" ",
{
"type":"p",
"hlId":"75c7af",
"class":"cell txt l",
"children":[
"Optimal treatment unknown and is often supportive"
]
},
" ",
{
"type":"p",
"hlId":"957ff0",
"class":"cell txt l",
"children":[
"Glucocorticoids may be used for more progressive disease"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31e2ec",
"class":"cell txt l",
"children":[
"Bleomycin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a7e31a",
"class":"cell txt l",
"children":[
"Risk significantly increases with cumulative dose"
]
},
" ",
{
"type":"p",
"hlId":"fd54cb",
"class":"cell txt l",
"children":[
"Increased age, kidney disease, concomitant chemotherapy or irradiation also increase risk for toxicity"
]
},
" ",
{
"type":"p",
"hlId":"0d9efe",
"class":"cell txt l",
"children":[
"Typically subacute presentation 1-6 months after exposure; may show hypersensitivity pneumonitis, diffuse alveolar damage, or usual interstitial pneumonia pathologically but with more rapid clinical onset and progressive course"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"180863",
"class":"cell txt l",
"children":[
"Imaging patterns suggest the multiple possible pathologic findings seen:"
]
},
" ",
{
"type":"p",
"hlId":"73ec94",
"class":"cell txt li",
"children":[
"Consolidation with ground glass (diffuse alveolar damage)"
]
},
" ",
{
"type":"p",
"hlId":"40b186",
"class":"cell txt li",
"children":[
"Septal line thickening, traction bronchiectasis, and honeycomb change (end-stage fibrosis)"
]
},
" ",
{
"type":"p",
"hlId":"b7815f",
"class":"cell txt li",
"children":[
"Patchy ground glass with subpleural consolidation or peribronchial consolidation (organizing pneumonia)"
]
},
" ",
{
"type":"p",
"hlId":"243201",
"class":"cell txt li",
"children":[
"Diffuse ground glass with centrilobular micronodules (hypersensitivity pneumonitis)"
]
},
" ",
{
"type":"p",
"hlId":"9954ab",
"class":"cell txt li",
"children":[
"Glucocorticoids used for more severe disease; disease may recur with tapering of steroids"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"HSCT = hematopoietic stem cell transplantation."
]
]
}